News Room

All Press Releases In The News Blogs
21 Feb 2017
Press Release
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of LHON 
Gensight (Euronext: SIGHT)
21 Feb 2017
Press Release
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia 
Minerva Neurosciences (NASDAQ: NERV)
16 Feb 2017
Press Release
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. 
Ariad (NASDAQ: ARIA) - Acquired by Takeda
09 Feb 2017
In The News
Newswire
XO1 Founding Management Team Re-Unite to Launch SuperX and Announce $11m Series A Funding With Medicxi and Johnson & Johnson Innovation-JJDC 
09 Feb 2017
Press Release
Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas – Ongoing strong cash position 
Molecular Partners (S​wiss​: MOLN.SW)
05 Feb 2017
In The News
The Times
How to make our spinouts graduate into new Googles 
03 Feb 2017
Press Release
Cambridge Enterprise joins in £14m funding round for spin-out ApcinteX Limited 
ApcinteX - Centessa Therapeutics (NASDAQ:CNTA)
31 Jan 2017
Press Release
Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer 
Versartis (NASDAQ: VSAR)
31 Jan 2017
Press Release
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa 
Gensight (Euronext: SIGHT)
30 Jan 2017
Press Release
Versartis' Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 
Versartis (NASDAQ: VSAR)
25 Jan 2017
Press Release
ObsEva SA Announces Pricing of Initial Public Offering 
ObsEva (NASDAQ: OBSV)
23 Jan 2017
In The News
Business Wire
Fierce MedicalDevices names Acutus Medical® as one of its “Fierce 15” Medical Device Companies of 2016 
20 Jan 2017
Press Release
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function 
Minerva Neurosciences (NASDAQ: NERV)
18 Jan 2017
Press Release
Egalet Closes Second Tranche of $80 Million Secured Debt Financing 
Egalet (NASDAQ:EGLT)
09 Jan 2017
Press Release
Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain 
Egalet (NASDAQ:EGLT)
04 Jan 2017
Press Release
Molecular Partners to Present at the 35th ANNUAL J.P. MORGAN Healthcare Conference 
Molecular Partners (S​wiss​: MOLN.SW)
20 Dec 2016
Press Release
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
20 Dec 2016
Press Release
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer 
Minerva Neurosciences (NASDAQ: NERV)
16 Dec 2016
Press Release
Egalet Announces Positive Top-Line Results from an Intranasal Human Abuse Potential Study of Egalet-002 
Egalet (NASDAQ:EGLT)
05 Dec 2016
Press Release
Minerva Neurosciences' Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting 
Minerva Neurosciences (NASDAQ: NERV)
07 Nov 2016
Press Release
Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society 
Versartis (NASDAQ: VSAR)
18 Oct 2016
Press Release
Fierce Biotech
Medicxi founds Parkinson’s startup, commits €9M 
29 Sep 2016
In The News
BioCentury Innovations
Emerging Company Profile: Composite T Cells 
08 Sep 2016
Press Release
GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy 
Gensight (Euronext: SIGHT)
01 Sep 2016
Press Release
The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa 
Gensight (Euronext: SIGHT)
11 Aug 2016
Press Release
GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option 
Gensight (Euronext: SIGHT)
04 Aug 2016
Press Release
Egalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO™ ER (Morphine Sulfate) and Reports Second Quarter 2016 Financial Results 
Egalet (NASDAQ:EGLT)
19 Jul 2016
Press Release
BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders 
Molecular Partners (S​wiss​: MOLN.SW)
12 Jul 2016
Press Release
French gene therapy firm GenSight raises 40 mln euros in IPO 
Gensight (Euronext: SIGHT)
08 Jun 2016
Press Release
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy 
Gensight (Euronext: SIGHT)
26 May 2016
Press Release
MIN-101 Meets Primary & Secondary Endpoints In Phase IIB Trial 
Minerva Neurosciences (NASDAQ: NERV)
26 May 2016
Press Release
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder 
Minerva Neurosciences (NASDAQ: NERV)
22 May 2016
Press Release
Acutus Medical Completes $75 Million Series C Financing 
Acutus Medical
18 May 2016
Press Release
Novel Ultrasound-based Imaging and Global Dipole Density Mapping: Feasibility in Persistent Atrial Fibrillation Heart Rhythm Society May 2016 Poster PO03 
Acutus Medical
30 Mar 2016
In The News
Nasdaq Globe Newswire
Palladio Biosciences, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Philadelphia Event 
29 Mar 2016
Press Release
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc. 
Padlock Therapeutics - Acquired by BMS
29 Mar 2016
Press Release
Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic 
Gadeta
11 Mar 2016
Press Release
Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 
Minerva Neurosciences (NASDAQ: NERV)
08 Mar 2016
Press Release
Antibody Firm Capella raises $15.5M for Novel Targets, Good Biology 
Capella - Centessa Therapeutics (NASDAQ:CNTA)
08 Mar 2016
Press Release
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline 
Capella - Centessa Therapeutics (NASDAQ:CNTA)
07 Mar 2016
In The News
FierceBiotech
Capella Bio Harnesses a Virtual Global Team to a Targeted Antibody R&D Strategy 
07 Mar 2016
Press Release
Molecular Partners Reveals Programs in Immuno-Oncology 
Molecular Partners (S​wiss​: MOLN.SW)
29 Feb 2016
Press Release
Egalet Announces FDA Acceptance of New Drug Application for ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets 
Egalet (NASDAQ:EGLT)
29 Feb 2016
Press Release
GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy 
Gensight (Euronext: SIGHT)
14 Feb 2016
In The News
Sunday Times
University spin-outs demand a better deal 
08 Feb 2016
In The News
BioCentury
Asset renaissance: How Medicxi increases Phase II success with less capital (subscription required) 
02 Feb 2016
In The News
FT
J&J and GSK join Medicxi’s European life sciences push 
02 Feb 2016
In The News
BioWorld
Zeroing in on early stage European research, Index launches $250M fund (subscription required) 
02 Feb 2016
In The News
Bloomberg
Index Ventures Spins Off Biotech Investment Arm Into New Firm 
02 Feb 2016
In The News
Reuters
Guess What This Early Skype Investor Is Betting on Now 
02 Feb 2016
In The News
SCRIP
INTERVIEW: Why Medicxi Spun Itself Out Of Index (subscription required) 
02 Feb 2016
In The News
Bilan
Medicxi, le spin-off à un milliard d’Index Ventures 
02 Feb 2016
Press Release
Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children 
Versartis (NASDAQ: VSAR)
02 Feb 2016
Blog
Who are the Medicxi founding team?
02 Feb 2016
Press Release
Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210m Fund including GSK and Johnson & Johnson Innovation
02 Feb 2016
Blog
The Formation of Medicxi
01 Feb 2016
In The News
FierceBiotech
Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund 
01 Feb 2016
Press Release
Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 
Minerva Neurosciences (NASDAQ: NERV)
11 Jan 2016
Press Release
Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 
Minerva Neurosciences (NASDAQ: NERV)
08 Jan 2016
Press Release
Aegerion Pharmaceuticals to Present at the 34th Annual J.P. Morgan 
Aegerion (NASDAQ: AEGR) - Novelion
04 Jan 2016
Press Release
Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease 
Addex (Swiss ADXN.SW)
21 Dec 2015
Press Release
Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen 
Genmab (Copenhagen: GEN.CO)
17 Dec 2015
Press Release
Egalet Added to NASDAQ Biotechnology Index 
Egalet (NASDAQ:EGLT)
16 Dec 2015
Press Release
Versartis' VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism 
Versartis (NASDAQ: VSAR)
15 Dec 2015
Press Release
Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma 
Novocure (NASDAQ: NVCR)
07 Dec 2015
Press Release
ARIAD Announces Initiation of OPTIC-2L Randomized Phase 3 Trial of ponatinib vs. nilotinib in Second-Line Patients with Chronic-Phase Chronic Myeloid Leukemia 
Ariad (NASDAQ: ARIA) - Acquired by Takeda
09 Nov 2015
Press Release
Acutus Medical Announces Presentation of AcQMap High Resolution Imaging and Mapping System Data at the 2015 American Heart Association Scientific Sessions 
Acutus Medical
19 Mar 2015
Press Release
Janssen Acquires XO1 Limited 
Xo1 - Janssen Pharmaceuticals (NYSE: JNJ)
19 Mar 2015
Blog
Janssen Pharmaceuticals acquires 100% of XO1
by Francesco De Rubertis
11 Feb 2015
Press Release
GlycoVaxyn AG sells its shares to GSK 
GlycoVaxyn - Acquired by GSK (London: GSK.L)
11 Feb 2015
Blog
Glycovaxyn: the vision of a brilliant ETHZ biochemist turns into reality
by Francesco De Rubertis
09 Jan 2015
Press Release
CoMentis and Anvyl Announce the Initiation of Clinical Trials for APN1125 for the Treatment of Schizophrenia 
CoMentis
18 Dec 2014
Press Release
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers 
Oncoethix - Acquired by Merck (NYSE.MRK)
17 Oct 2013
Blog
Clinical Trial Transparency
by David Grainger
04 Sep 2013
Blog
Platform Technologies
by David Grainger
14 Aug 2013
Blog
The Man Who Cured Ageing?
by David Grainger
06 Aug 2013
Blog
ProFibrix, a rising star of pharma companies
by Francesco De Rubertis
31 Jul 2013
Blog
The zero person biotech company
by David Grainger
16 Jul 2013
Blog
Incremental innovation lives on
by David Grainger
17 Jun 2013
Blog
Ichorcumab: the blood of the gods?
by David Grainger
20 May 2013
Blog
Where to start an ‘Asset-Centric’ Biotech Firm?
by Kevin Johnson
25 Oct 2012
Blog
Gianni Garotta: on to the next thing
by Francesco De Rubertis
19 Oct 2012
Blog
Playground 1.0
by Kevin Johnson
17 Oct 2012
Blog
The Lionel Messi of Biology?
by Francesco De Rubertis
16 Apr 2012
Blog
There’s something about entrepreneurs
by Kevin Johnson
21 Mar 2012
Blog
The Index Asset-Centric Platform
by Kevin Johnson
21 Mar 2012
Blog
The “Asset Centric” investing model
by Michèle Ollier
16 Mar 2012
Blog
Micromet: a BiTE at cancer?
by Francesco De Rubertis
07 Feb 2012
Blog
Is "more" always "better" for biotech start ups?
by Francesco De Rubertis